AstraZeneca is paying $600 million upfront in a licensing deal worth up to $1.5 billion for exclusive global rights to Dizal Pharmaceutical’s Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor already approved in China and the U.S. for previously treated EGFR exon 20 insertion-mutant non–small-cell lung cancer. The deal gives AstraZeneca a late-stage, differentiated targeted therapy backed by the pivotal WU-KONG6 study in China and the Phase I/II WU-KONG1 Part B trial in the U.S., with first-line filings now under review based on Phase III WU-KONG28 data.

Why It Matters To Oncology

• Zegfrovy targets a hard-to-treat molecular subset of NSCLC: tumors harboring EGFR exon 20 insertion mutations.

• Its oral small-molecule profile could offer a differentiated option versus infused competitors, particularly if first-line approval is secured.

• For clinicians, the asset expands the competitive landscape in precision lung cancer and underscores continued investment in mutation-specific drug discovery.

The Financials

• AstraZeneca will pay $600 million upfront for exclusive global development and commercialization rights.

• Dizal is eligible for up to $900 million in additional milestone payments, plus tiered sales royalties.

• Dizal shares rose nearly 20% after the announcement.

What They're Saying

• Dave Fredrickson, executive VP of AstraZeneca’s oncology haematology business unit, said the agreement will help bring “a differentiated, oral targeted treatment” to patients with limited options globally.

• The messaging positions Zegfrovy as both a commercial asset and a strategic fit for AstraZeneca’s oncology portfolio.

What's Next

• Dizal has filed for first-line approval in China and the U.S. for EGFR exon 20 insertion NSCLC, supported by Phase III WU-KONG28 data.

• If authorized in the front-line setting, Zegfrovy would compete with Johnson & Johnson’s Rybrevant, which is FDA-approved with chemotherapy in this population.

• Regulatory decisions and any eventual label expansion will determine how quickly AstraZeneca can scale the drug globally.